These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16889230)

  • 1. Advances in cathepsin S inhibitor design.
    Link JO; Zipfel S
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):471-82. PubMed ID: 16889230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a potent and selective noncovalent cathepsin S inhibitor.
    Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
    J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
    Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
    Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin S inhibitors as novel immunomodulators.
    Thurmond RL; Sun S; Karlsson L; Edwards JP
    Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteine cathepsin S as an immunomodulatory target: present and future trends.
    Gupta S; Singh RK; Dastidar S; Ray A
    Expert Opin Ther Targets; 2008 Mar; 12(3):291-9. PubMed ID: 18269339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
    Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
    Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in cathepsin K inhibitor design.
    Grabowskal U; Chambers TJ; Shiroo M
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity.
    Baugh M; Black D; Westwood P; Kinghorn E; McGregor K; Bruin J; Hamilton W; Dempster M; Claxton C; Cai J; Bennett J; Long C; McKinnon H; Vink P; den Hoed L; Gorecka M; Vora K; Grant E; Percival MD; Boots AM; van Lierop MJ
    J Autoimmun; 2011 May; 36(3-4):201-9. PubMed ID: 21439785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
    Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
    Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
    Yasuda Y; Kaleta J; Brömme D
    Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.
    Asagiri M; Hirai T; Kunigami T; Kamano S; Gober HJ; Okamoto K; Nishikawa K; Latz E; Golenbock DT; Aoki K; Ohya K; Imai Y; Morishita Y; Miyazono K; Kato S; Saftig P; Takayanagi H
    Science; 2008 Feb; 319(5863):624-7. PubMed ID: 18239127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the design of cathepsin S inhibitors.
    Wiener JJ; Sun S; Thurmond RL
    Curr Top Med Chem; 2010; 10(7):717-32. PubMed ID: 20337580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin S inhibitors: 2004-2010.
    Lee-Dutra A; Wiener DK; Sun S
    Expert Opin Ther Pat; 2011 Mar; 21(3):311-37. PubMed ID: 21342054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin G is differentially expressed in primary human antigen-presenting cells.
    Stoeckle C; Sommandas V; Adamopoulou E; Belisle K; Schiekofer S; Melms A; Weber E; Driessen C; Boehm BO; Tolosa E; Burster T
    Cell Immunol; 2009; 255(1-2):41-5. PubMed ID: 19036358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases.
    Ratcliffe AJ
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):595-605. PubMed ID: 17002220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific cathepsin B inhibitor is cell-permeable and activates presentation of TTC in primary human dendritic cells.
    Reich M; Wieczerzak E; Jankowska E; Palesch D; Boehm BO; Burster T
    Immunol Lett; 2009 Apr; 123(2):155-9. PubMed ID: 19428564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S.
    Chatterjee AK; Liu H; Tully DC; Guo J; Epple R; Russo R; Williams J; Roberts M; Tuntland T; Chang J; Gordon P; Hollenbeck T; Tumanut C; Li J; Harris JL
    Bioorg Med Chem Lett; 2007 May; 17(10):2899-903. PubMed ID: 17382545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cysteine protease cathepsin S as a key step in antigen presentation.
    Liu W; Spero DM
    Drug News Perspect; 2004; 17(6):357-63. PubMed ID: 15334187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel cathepsin S inhibitors by pharmacophore-based virtual high-throughput screening.
    Markt P; McGoohan C; Walker B; Kirchmair J; Feldmann C; De Martino G; Spitzer G; Distinto S; Schuster D; Wolber G; Laggner C; Langer T
    J Chem Inf Model; 2008 Aug; 48(8):1693-705. PubMed ID: 18637674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.
    Morley AD; Kenny PW; Burton B; Heald RA; Macfaul PA; Mullett J; Page K; Porres SS; Ribeiro LR; Smith P; Ward S; Wilkinson TJ
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1658-61. PubMed ID: 19231183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.